Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasm Metastasis 11Carcinoma, Hepatocellular 7Colorectal Neoplasms 6Liver Neoplasms 5Rectal Neoplasms 4Colonic Neoplasms 4Pancreatic Neoplasms 3Lung Neoplasms 3Kidney Neoplasms 3Breast Neoplasms 3Pain 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Thymoma 1Small Cell Lung Carcinoma 1Sarcoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Multiple Advanced Tumors After PD-1 Therapy Failure 1Mesothelioma, Malignant 1Jaundice, Obstructive 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Cancer Liver Metastases 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1

Interventions

Radiofrequency Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Multiple Advanced Tumors After PD-1 Therapy Failure × Radiofrequency Ablation × Clear all
NCT07095803 2025-07-31

Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure

Fudan University

Phase 2 Not yet recruiting
60 enrolled

Multiple Advanced Tumors After PD-1 Therapy Failure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡